tradingkey.logo
搜索

Myriad Genetics Inc

MYGN
添加自选
4.140USD
+0.130+3.24%
收盘 09-24 16:00(美东)
391.02M总市值
亏损市盈率 TTM

关于 Myriad Genetics Inc 公司

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Myriad Genetics Inc 简介

公司代码MYGN
公司名称Myriad Genetics Inc
上市日期Oct 06, 1995
CEORaha (Samraat S)
员工数量2700
证券类型Ordinary Share
年结日Oct 06
公司地址322 North 2200 West
城市SALT LAKE CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编84116
电话18015843600
网址https://myriad.com/
公司代码MYGN
上市日期Oct 06, 1995
CEORaha (Samraat S)

Myriad Genetics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--

常见问题

Myriad Genetics Inc的前五大股东是谁?

Myriad Genetics Inc 的前五大股东如下:Mr. Mark S. Verratti

有多少机构持有Myriad Genetics Inc(MYGN)的股份?

截至2026Q1,共有539家机构持有Myriad Genetics Inc的股份,合计持有的股份价值约为102.95M,占公司总股份的109.00%。与2025Q4相比,机构持股有所增加,增幅为-7290509.00。

哪个业务部门对Myriad Genetics Inc的收入贡献最大?

在2026Q1,Hereditary Cancer业务部门对Myriad Genetics Inc的收入贡献最大,创收114.10M,占总收入的59.83%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有